Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Chemotherapy, and Image-Guided Surgery for Malignant Pleural Mesothelioma
NCT03760575Phase 1Recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2023
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in malignant pleural mesothelioma (MPM), sponsored by Abramson Cancer Center. Primary endpoint: Adverse Events. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03760575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760575.